Samsung Epis Holdings Co., Ltd. (0126Z0)

Overview

Samsung Epis Holdings Co., Ltd. is a biopharmaceutical holding company dedicated to managing and advancing strategic investments within the biotechnology sector. The company's primary areas of focus are on biosimilars and next-generation therapeutics. It oversees various subsidiaries, including Samsung Bioepis, which is recognized as a leading developer and manufacturer of high-quality biosimilars. Additionally, Epis NexLab is committed to creating innovative biotechnology platforms that facilitate future drug discovery.

Samsung Epis Holdings plays a pivotal role in supporting research and development across multiple therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. The company's mission is to address unmet medical needs and expand its global footprint. By leveraging scalable platform technologies—especially in peptide-based drug development—Samsung Epis Holdings fosters collaborative efforts with global pharmaceutical partners. This strategic approach separates its biosimilar operations from contract manufacturing, enabling focused growth and enhancing operational flexibility and independent decision-making within the biotech sector.

Listed on the South Korea Stock Exchange, Samsung Epis Holdings maintains a commitment to sustainable innovation and strives to create long-term value for shareholders and patients on a global scale.

Products and Services

• Biosimilars: Samsung Bioepis, a subsidiary under Samsung Epis Holdings, is at the forefront of developing and manufacturing high-quality biosimilars. These products aim to provide affordable alternatives to expensive biologic therapies, thereby improving access to vital treatments for patients worldwide.
• Next-Generation Therapeutics: The company emphasizes the research and development of innovative therapeutics that address current gaps in treatment options. These advanced therapies are designed to deliver improved efficacy and minimize side effects, enhancing the overall patient experience.
• Biotech Platforms: Through Epis NexLab, Samsung Epis Holdings is dedicated to creating cutting-edge biotechnology platforms that facilitate drug discovery. These platforms leverage the latest technological advancements to enhance the development processes and bring new therapeutic solutions to market more efficiently.
• Research and Development Support: The company actively invests in R&D across various therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. This broad focus ensures a comprehensive approach to tackling unmet medical needs through innovative science.
• Collaborations with Pharmaceutical Partners: Samsung Epis Holdings fosters collaborations with global pharmaceutical companies, enhancing its capabilities in the development and commercialization of new therapies. These partnerships facilitate knowledge sharing and resource optimization, ultimately benefiting patients and healthcare systems globally.